메뉴 건너뛰기




Volumn 97, Issue 5, 2015, Pages 488-491

Innovative Clinical Trials: The LUNG-MAP Study

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR MARKER;

EID: 84965086826     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.88     Document Type: Article
Times cited : (59)

References (22)
  • 1
    • 84918804764 scopus 로고    scopus 로고
    • First-line crizotinib versus chemotherapy in ALK-positive lung cancer
    • Solomon, B.J. et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167–2177 (2014).
    • (2014) N. Engl. J. Med. , vol.371 , pp. 2167-2177
    • Solomon, B.J.1
  • 2
    • 84857502654 scopus 로고    scopus 로고
    • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
    • Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239–246 (2012).
    • (2012) Lancet Oncol , vol.13 , pp. 239-246
    • Rosell, R.1
  • 4
    • 84866894408 scopus 로고    scopus 로고
    • Comprehensive genomic characterization of squamous cell lung cancers
    • Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 489, 519–525 (2012).
    • (2012) Nature , vol.489 , pp. 519-525
  • 5
    • 84906851561 scopus 로고    scopus 로고
    • New clinical research strategies in thoracic oncology: Clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
    • Menis, J., Hasan, B. & Besse, B. New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. Eur. Respir. Rev. 23, 367–378 (2014).
    • (2014) Eur. Respir. Rev. , vol.23 , pp. 367-378
    • Menis, J.1    Hasan, B.2    Besse, B.3
  • 6
    • 79957857433 scopus 로고    scopus 로고
    • The BATTLE trial: Personalizing therapy for lung cancer
    • Kim, E.S. et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 1, 44–53 (2011).
    • (2011) Cancer Discov , vol.1 , pp. 44-53
    • Kim, E.S.1
  • 7
    • 84893362995 scopus 로고    scopus 로고
    • Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC
    • Champiat, S. et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J. Thorac. Oncol. 9, 144–153 (2014).
    • (2014) J. Thorac. Oncol. , vol.9 , pp. 144-153
    • Champiat, S.1
  • 8
    • 84937518516 scopus 로고    scopus 로고
    • Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: Metastatic non-small cell lung cancer
    • Ramalingam, S.S. et al. Phase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer: metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 90, 1266–1267 (2014).
    • (2014) Int. J. Radiat. Oncol. Biol. Phys. , vol.90 , pp. 1266-1267
    • Ramalingam, S.S.1
  • 10
    • 85138528304 scopus 로고    scopus 로고
    • Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody
    • Segal, N. et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Chicago: ASCO.
    • Chicago: ASCO.
  • 11
    • 13944284494 scopus 로고    scopus 로고
    • Oncogenic mutations of PIK3CA in human cancers
    • Samuels, Y. & Velculescu, V.E. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 3, 1221–1224 (2004).
    • (2004) Cell Cycle , vol.3 , pp. 1221-1224
    • Samuels, Y.1    Velculescu, V.E.2
  • 12
    • 8444240824 scopus 로고    scopus 로고
    • Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression
    • Massion, P.P. et al. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am. J. Respir. Crit. Care Med. 170, 1088–1094 (2004).
    • (2004) Am. J. Respir. Crit. Care Med. , vol.170 , pp. 1088-1094
    • Massion, P.P.1
  • 13
    • 84879056371 scopus 로고    scopus 로고
    • Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyra-zol-1-yl}-2-methylpropanamide (GDC-0032): A beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity
    • Ndubaku, C.O. et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyra-zol-1-yl}-2-methylpropanamide (GDC-0032): A beta-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. J. Med. Chem. 56, 4597–4610 (2013).
    • (2013) J. Med. Chem. , vol.56 , pp. 4597-4610
    • Ndubaku, C.O.1
  • 14
    • 33645802169 scopus 로고    scopus 로고
    • Cyclin-dependent kinase pathways as targets for cancer treatment
    • Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).
    • (2006) J. Clin. Oncol. , vol.24 , pp. 1770-1783
    • Shapiro, G.I.1
  • 15
    • 84922369296 scopus 로고    scopus 로고
    • The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study
    • Finn, R.S. et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16, 25–35 (2015).
    • (2015) Lancet Oncol , vol.16 , pp. 25-35
    • Finn, R.S.1
  • 16
    • 84880695940 scopus 로고    scopus 로고
    • Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma
    • Dickson, M.A. et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J. Clin. Oncol. 31, 2024–2028 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , pp. 2024-2028
    • Dickson, M.A.1
  • 17
    • 84860120185 scopus 로고    scopus 로고
    • AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family
    • Gavine, P.R. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045–2056 (2012).
    • (2012) Cancer Res , vol.72 , pp. 2045-2056
    • Gavine, P.R.1
  • 18
    • 84871217393 scopus 로고    scopus 로고
    • Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models
    • Zhang, J. et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin. Cancer Res. 18, 6658–6667 (2012).
    • (2012) Clin. Cancer Res. , vol.18 , pp. 6658-6667
    • Zhang, J.1
  • 19
    • 84937637414 scopus 로고    scopus 로고
    • A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data
    • Paik, P. et al. A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumor activity and pharmacodynamic data. Clin Oncol 32, 5s, (2014).
    • (2014) Clin Oncol , vol.5s , pp. 32
    • Paik, P.1
  • 20
    • 13944276728 scopus 로고    scopus 로고
    • Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
    • Ma, P.C. et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65, 1479–1488 (2005).
    • (2005) Cancer Res , vol.65 , pp. 1479-1488
    • Ma, P.C.1
  • 21
    • 38649119730 scopus 로고    scopus 로고
    • Signaling networks assembled by oncogenic EGFR and c-Met
    • Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. U. S. A. 105, 692–697 (2008).
    • (2008) Proc. Natl. Acad. Sci. U. S. A. , vol.105 , pp. 692-697
    • Guo, A.1
  • 22
    • 70349315347 scopus 로고    scopus 로고
    • Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs
    • Richey, E.A. et al. Accelerated approval of cancer drugs: Improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs, J. Clin. Oncol. 27, 4398–4405 (2009).
    • (2009) J. Clin. Oncol. , vol.27 , pp. 4398-4405
    • Richey, E.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.